These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23766442)

  • 1. Progress towards butyrate-producing pharmabiotics: Butyricicoccus pullicaecorum capsule and efficacy in TNBS models in comparison with therapeutics.
    Eeckhaut V; Ducatelle R; Sas B; Vermeire S; Van Immerseel F
    Gut; 2014 Feb; 63(2):367. PubMed ID: 23766442
    [No Abstract]   [Full Text] [Related]  

  • 2. Butyricicoccus pullicaecorum in inflammatory bowel disease.
    Eeckhaut V; Machiels K; Perrier C; Romero C; Maes S; Flahou B; Steppe M; Haesebrouck F; Sas B; Ducatelle R; Vermeire S; Van Immerseel F
    Gut; 2013 Dec; 62(12):1745-52. PubMed ID: 23263527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Butyrate-producing bacteria as pharmabiotics for inflammatory bowel disease.
    Marteau P
    Gut; 2013 Dec; 62(12):1673. PubMed ID: 23461897
    [No Abstract]   [Full Text] [Related]  

  • 4. In vitro characterization of gastrointestinal behavior of Butyricicoccus pullicaecorum, a novel butyrate producing isolate with probiotic potential to counterbalance dysbiosis in inflammatory bowel disease.
    Geirnaert A; Steyaert A; Van den Abbeele P; Eeckhaut V; Van Immerseel F; Boon N; Van de Wiele T
    Commun Agric Appl Biol Sci; 2013; 78(1):157-63. PubMed ID: 23875313
    [No Abstract]   [Full Text] [Related]  

  • 5. Butyricicoccus pullicaecorum gen. nov., sp. nov., an anaerobic, butyrate-producing bacterium isolated from the caecal content of a broiler chicken.
    Eeckhaut V; Van Immerseel F; Teirlynck E; Pasmans F; Fievez V; Snauwaert C; Haesebrouck F; Ducatelle R; Louis P; Vandamme P
    Int J Syst Evol Microbiol; 2008 Dec; 58(Pt 12):2799-802. PubMed ID: 19060061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced Mucosa-associated Butyricicoccus Activity in Patients with Ulcerative Colitis Correlates with Aberrant Claudin-1 Expression.
    Devriese S; Eeckhaut V; Geirnaert A; Van den Bossche L; Hindryckx P; Van de Wiele T; Van Immerseel F; Ducatelle R; De Vos M; Laukens D
    J Crohns Colitis; 2017 Feb; 11(2):229-236. PubMed ID: 27484096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro evaluation of the upper gastrointestinal passage of a novel butyrate producing isolate to counterbalance dysbiosis in inflammatory bowel disease.
    Geirnaert A; Debruyne B; Eeckhaut V; Van Immerseel F; Boon N; Van de Wiele T
    Commun Agric Appl Biol Sci; 2012; 77(1):195-9. PubMed ID: 22558780
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety assessment of the butyrate-producing Butyricicoccus pullicaecorum strain 25-3(T), a potential probiotic for patients with inflammatory bowel disease, based on oral toxicity tests and whole genome sequencing.
    Steppe M; Van Nieuwerburgh F; Vercauteren G; Boyen F; Eeckhaut V; Deforce D; Haesebrouck F; Ducatelle R; Van Immerseel F
    Food Chem Toxicol; 2014 Oct; 72():129-37. PubMed ID: 25007784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Butyrate Producers as Potential Next-Generation Probiotics: Safety Assessment of the Administration of
    Boesmans L; Valles-Colomer M; Wang J; Eeckhaut V; Falony G; Ducatelle R; Van Immerseel F; Raes J; Verbeke K
    mSystems; 2018; 3(6):. PubMed ID: 30417112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Butyricicoccus pullicaecorum, a butyrate producer with probiotic potential, is intrinsically tolerant to stomach and small intestine conditions.
    Geirnaert A; Steyaert A; Eeckhaut V; Debruyne B; Arends JB; Van Immerseel F; Boon N; Van de Wiele T
    Anaerobe; 2014 Dec; 30():70-4. PubMed ID: 25179909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interindividual differences in response to treatment with butyrate-producing Butyricicoccus pullicaecorum 25-3T studied in an in vitro gut model.
    Geirnaert A; Wang J; Tinck M; Steyaert A; Van den Abbeele P; Eeckhaut V; Vilchez-Vargas R; Falony G; Laukens D; De Vos M; Van Immerseel F; Raes J; Boon N; Van de Wiele T
    FEMS Microbiol Ecol; 2015 Jun; 91(6):. PubMed ID: 25999470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intestinal microflora and chronic inflammatory bowel diseases].
    Desreumaux P; Colombel JF
    Gastroenterol Clin Biol; 2001 Sep; 25(2 Pt 2):C89-93. PubMed ID: 11787387
    [No Abstract]   [Full Text] [Related]  

  • 13. Probiotic bacteria in the prevention and the treatment of inflammatory bowel disease.
    Fedorak R; Demeria D
    Gastroenterol Clin North Am; 2012 Dec; 41(4):821-42. PubMed ID: 23101689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probiotics and IBD.
    De Greef E; Vandenplas Y; Hauser B; Devreker T; Veereman-Wauters G
    Acta Gastroenterol Belg; 2013 Mar; 76(1):15-9. PubMed ID: 23650777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Crohn disease, ulcerative colitis. When bacteria attack the intestinal wall....].
    Duchmann R; Lochs H; Kruis W
    MMW Fortschr Med; 1999 Dec; 141(51-52):48-51. PubMed ID: 10949626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycobacteria and inflammatory bowel disease.
    Stanford JL; White SA; Burnham WR; Lennard-Jones JE; Bird RG
    Lancet; 1979 Feb; 1(8113):444. PubMed ID: 84294
    [No Abstract]   [Full Text] [Related]  

  • 17. Human microbiota and inflammatory bowel diseases: new pieces of an intricate puzzle.
    Pellicano R
    Minerva Gastroenterol Dietol; 2019 Sep; 65(3):171-172. PubMed ID: 31602969
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical utility of probiotics in inflammatory bowel disease.
    Cain AM; Karpa KD
    Altern Ther Health Med; 2011; 17(1):72-9. PubMed ID: 21614946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Executive summary of the AGA-NFIC sponsored workshop on infectious agents in inflammatory bowel disease.
    Thayer WR
    Dig Dis Sci; 1979 Oct; 24(10):781-4. PubMed ID: 487915
    [No Abstract]   [Full Text] [Related]  

  • 20. In vitro evaluation of the upper gastrointestinal passage of a novel butyrate producing isolate to counterbalance dysbiosis in inflammatory bowel disease.
    Geirnaert A; Debruyne B; Eeckhaut V; Van Immerseel F; Booni N; Van de Wiele T
    Commun Agric Appl Biol Sci; 2012; 77(1):45-9. PubMed ID: 22558754
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.